D-pharm inks $22M Chinese licensing pact

Israel's D-pharm has struck a $22.5 million licensing deal with a Chinese pharma company for its late-stage stroke-prevention drug. Wanbang Biopharmaceuticals will pay for the Chinese trial costs of DP-b99, which is currently in Phase III. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.